Volume 89 Issue 21 | p. 23 | Concentrates
Issue Date: May 23, 2011

Merck, Roche Team Up For Hepatitis Drug

Department: Business | Collection: Special Issue
Keywords: Victrelis, boceprevir, hepatitis C

Merck & Co. has received FDA approval for the protease inhibitor boceprevir to be used in combination with PEGylated interferon and ribavirin for treating hepatitis C virus (HCV) infection. To be marketed as Victrelis, the drug is the first new HCV treatment in more than a decade. Just days after getting the regulatory nod, Merck signed a nonexclusive pact with Roche, under which the Swiss company will promote Victrelis alongside Pegasys, a PEGylated interferon. The deal is expected to give Merck a leg up on Vertex Pharmaceuticals, which is poised to win approval for its own HCV treatment, telaprevir. Merck and Roche will also work together to explore novel combinations of HCV drugs.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment